| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
PYRIPYROPENE A
ID: ALA179229
Max Phase: Preclinical
Molecular Formula: C31H35NO10
Molecular Weight: 581.62
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CC(=O)OCC1(C)C(OC(C)=O)CCC2(C)C3C(=O)C4=C(O)OC(c5cccnc5)C=C4OC3(C)C(OC(C)=O)=CC12
Standard InChI: InChI=1S/C31H35NO10/c1-16(33)38-15-30(5)22-13-24(40-18(3)35)31(6)27(29(22,4)10-9-23(30)39-17(2)34)26(36)25-21(42-31)12-20(41-28(25)37)19-8-7-11-32-14-19/h7-8,11-14,20,22-23,27,37H,9-10,15H2,1-6H3
Standard InChI Key: OTULVINLEZVILJ-UHFFFAOYSA-N
Associated Targets(Human)
Acyl coenzyme A:cholesterol acyltransferase 2 288 Activities
Acyl coenzyme A:cholesterol acyltransferase 1 857 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Acyl coenzyme A:cholesterol acyltransferase 1 2344 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 581.62 | Molecular Weight (Monoisotopic): 581.2261 | AlogP: 4.16 | #Rotatable Bonds: 5 |
| Polar Surface Area: 147.55 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 1 |
| #RO5 Violations: 2 | HBA (Lipinski): 11 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: 8.60 | CX Basic pKa: 4.67 | CX LogP: 1.81 | CX LogD: 1.78 |
| Aromatic Rings: 1 | Heavy Atoms: 42 | QED Weighted: 0.39 | Np Likeness Score: 1.51 |
References
| 1. Jeong TS, Kim KS, Yu H, Kim MJ, Cho KH, Choi YK, Kim HC, Park HY, Lee WS.. (2005) Saucerneol B derivatives as human acyl-CoA: cholesterol acyltransferase inhibitors., 15 (2): [PMID:15603959] [10.1016/j.bmcl.2004.10.066] |
| 2. Xu MZ, Lee WS, Kim MJ, Park DS, Yu H, Tian GR, Jeong TS, Park HY.. (2004) Acyl-CoA: cholesterol acyltransferase inhibitory activities of fatty acid amides isolated from Mylabris phalerate Pallas., 14 (16): [PMID:15261286] [10.1016/j.bmcl.2004.05.086] |
| 3. Ohtawa M, Yamazaki H, Ohte S, Matsuda D, Ohshiro T, Rudel LL, Omura S, Tomoda H, Nagamitsu T.. (2013) Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors: part 1., 23 (5): [PMID:23369538] [10.1016/j.bmcl.2012.12.099] |
| 4. Ohtawa M, Yamazaki H, Ohte S, Matsuda D, Ohshiro T, Rudel LL, Ōmura S, Tomoda H, Nagamitsu T.. (2013) Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors: part 3., 23 (13): [PMID:23711919] [10.1016/j.bmcl.2013.04.075] |
Source
Source(1):